drug treatment of metastatic breast cancer fda approval overview patricia cortazar, md
TRANSCRIPT
Drug Treatment of Metastatic Breast Cancer
FDA Approval OverviewFDA Approval Overview
Patricia Cortazar, MDPatricia Cortazar, MD
Drugs approved for Metastatic Breast Cancer
MethotrexateMethotrexate 19531953 CyclophosphamideCyclophosphamide 19591959 ThiotepaThiotepa 19591959 VinblastineVinblastine 19611961 5-Fluorouracil5-Fluorouracil 19621962 DoxorubicinDoxorubicin 19741974
PaclitaxelPaclitaxel 19941994 DocetaxelDocetaxel 19961996 Trastuzumab Trastuzumab 19981998 CapecitabineCapecitabine 19981998 Capecitabine + DocetaxelCapecitabine + Docetaxel 20012001 AbraxaneAbraxane 20052005 LapatinibLapatinib 20062006 IxabepiloneIxabepilone 20072007
Drugs approved in 2nd-3rd line Metastatic Breast
Cancer
Paclitaxel
TAXOL® is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
Paclitaxel 135 mg/m2
3-hour infusion
TAXOL Study Design
Paclitaxel 175 mg/m2
3-hour infusion
471
Patients who failed one or two regimensof chemotherapy67% previous anthracyclines
TAXOL Efficacy ResultsFull Approval
Paclitaxel Paclitaxel 175175
235235
Paclitaxel 135Paclitaxel 135
236236
Response (months)(months) 28% 22%
P-value (log P-value (log rank)rank)
p=0.135
TTPTTP median median (months)(months)
4.24.2 3.03.0
P-value (log rank)P-value (log rank) p=0.027
Survival (months) (months) 11.711.7 10.510.5
P-value (log P-value (log rank)rank)
p=0.321
Docetaxel
TAXOTERE® for Injection indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy
DocetaxelAccelerated Approval 1996
3 Phase II studies in total 134 patients3 Phase II studies in total 134 patients Dose 100 mg/mDose 100 mg/m22 q 3 weeks q 3 weeks Endpoint: Endpoint: Overall RROverall RR
41%41% (95% CI: 33-49) (95% CI: 33-49) PMC: Submit data from controlled PMC: Submit data from controlled
clinical studies (TAX311, TAX304)clinical studies (TAX311, TAX304)
Mytomicin 12 mg/m2
Q 6 weeks Vinblastine 6 mg/m2
Q 3 weeks
TAX304 Study DesignTAX304 Study Design
Docetaxel 100 mg/m2
Q 3 weeks
392
Patients with Prior anthracyclineregimens
TAX304 Efficacy ResultsFull Approval
DocetaxelDocetaxel
203203Myt Myt
+Vinblastine+Vinblastine
189189
TTP (months)(months) 4.3 2.5
Risk Ratio 95% CI (RR)
0.750.61-0.94
P-value (log P-value (log rank)rank)
p=0.01
SurvivalSurvival (months) (months) 11.411.4 8.78.7
Risk Ratio* 95% CI (RR)
0.73
0.58-0.93
P-value (log P-value (log rank)rank)
p=0.01
Trastuzumab
HerceptinHerceptin®® is indicated for treatment of is indicated for treatment of patients with metastatic breast cancer patients with metastatic breast cancer whose tumors overexpress the HER2 whose tumors overexpress the HER2 protein and who have received one or protein and who have received one or more chemotherapy regimens for their more chemotherapy regimens for their metastatic disease. metastatic disease.
Trastuzumab 4 mg/kg loading dose2 mg/kg wkly maintenance
Herceptin MBC Study Design
222
Patients with MBCHER2 overexpression2+3+1 or 2 prior CT for MBCAnthracycline and Taxane
Herceptin monotherapy Full Approval
Response RateResponse Rate 14%14%
CRCR 2%2%
PRPR 12%12%
Response Duration median Response Duration median (months)(months)
99
Survival median (months)Survival median (months) 12.812.8
Capecitabine
Xeloda® is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents.
Capecitabine monotherapy Accelerated Approval
Patients resistant to paclitaxel Patients resistant to paclitaxel and anthracyclineand anthracycline
4343
CRCR 00
PRPR 1111
Response RateResponse Rate
95% CI95% CI25.6%25.6%
(13.5, (13.5, 41.2)41.2)
Response Duration median Response Duration median (days)(days)
RangeRange
154154
(63-233)(63-233)
Capecitabine
Xeloda® is indicated in combinationwith Taxotere (docetaxel) for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.
Docetaxel 100 mg/m2
Q 3 weeks
Study Design
Capecitabine 1250 mg/m2
twice daily for 14 days Docetaxel 75 mg/m2
Q 3 weeks
511
metastaticbreast cancer resistant to Anthracycline30% 1st line
Capecitabine Efficacy Results
Full ApprovalCapeciabine Capeciabine + Docetaxel+ Docetaxel
DocetaxelDocetaxel
TTPTTP (median days)(median days) 186 128
95% CI (165-198)(165-198) (105-136)(105-136)
Hazard RatioHazard Ratio 0.6430.643
P-value (log rank)P-value (log rank) p=0.01
SurvivalSurvival (median (median days)days)
442442 352352
95% CI95% CI (375-497)(375-497) (298-387)(298-387)
Hazard RatioHazard Ratio 0.775
P-value (log rank)P-value (log rank) 0.0126
Overall SurvivalOverall Survivalmedian days
Docetaxel ---- 352Capecitabine + Doc ---- 442
Log rank p=0.0126
Lapatinib
TYKERB® in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors over-express HER2 (ErbB2) who have received prior therapy including an anthracycline, a taxane and trastuzumab.
Capecitabine 2500 mg/m2 daily for 14 days
Study Design
Lapatinib 1250 mg/m2
continuouslyCapecitabine 2000 mg/m2
daily for 14 days
399
Locally advancedor metastaticbreast cancerHER2+ prior anthracycline,Taxane andHerceptin.
Lapatinib Efficacy ResultsFull Approval
Independent Independent radiology radiology ReviewReview
InvestigatorInvestigator
Lap Lap +Cap+Cap
CapCap Lap Lap +Cap+Cap
CapCap
TTPTTP # events# events 82 102 121 126126
Median (weeks)Median (weeks) 27.127.1 18.618.6 23.923.9 18.318.3
Hazard ratio Hazard ratio
95% CI95% CI0.570.57
(0.43, 0.77)(0.43, 0.77)0.720.72
(0.56, 0.92)(0.56, 0.92)
P-valueP-value 0.000130.00013 0.00762
ORRORR %% 23.723.7 13.913.9 31.831.8 17.417.4
Efficacy of Combination Therapy:Efficacy of Combination Therapy:Kaplan-Meier Curves of TTPKaplan-Meier Curves of TTP
Lapatinib + Capecitabine -----------
Capecitabine ---------
p= 0.00013
IxabepiloneCombination Therapy:Ixempra is indicated in combination with
capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant or for whom further anthracycline therapy is contraindicated.
Capecitabine 1250 mg/m2
BID Days 1 to 14 q 21 days
Study Design
Ixabepilone 40 mg/m2
Days 1 q 21 days Capecitabine 1000 mg/m2
BID Days 1 to 14 q 21 days752
Resistant to Taxane andanthracycline
Ixabepilone Efficacy ResultsFull Approval
Ixa + CapeIxa + Cape
375375CapecitabineCapecitabine
377377
PFSPFS (months)(months) 5.7 4.1
Hazard Ratio 95% CI
0.690.58-0.83
P-value (log P-value (log rank)rank)
p <0.0001p <0.0001
Efficacy of Combination Therapy:Kaplan-Meier Curves of PFS
log rank p< 0.0001
Ixabepilone
Monotherapy:Ixempra is indicated as monotherapy for
the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.
Single-arm Monotherapy Studies (n=126)
IndependenIndependent radiology t radiology
ReviewReview
InvestigatorInvestigator
ORRORR (%)(%) 12.4 18.3
95% CI95% CI 6.9, 19.96.9, 19.9 11.9, 26.111.9, 26.1
Response Duration
Median (months)Median (months) 6.06.0
95% CI95% CI 5.0, 7.6
1st line Metastatic Breast
Cancer
Drugs approved in 1st line Metastatic Breast Cancer
Herceptin + PaclitaxelHerceptin + Paclitaxel 19981998
Gemcitabine + PaclitaxelGemcitabine + Paclitaxel 20042004
Trastuzumab
HerceptinHerceptin®® in combination with in combination with paclitaxel is indicated for treatment of paclitaxel is indicated for treatment of patients with metastatic breast cancer patients with metastatic breast cancer whose tumors overexpress HER2 whose tumors overexpress HER2 protein and who have not received protein and who have not received chemotherapy for their metastatic chemotherapy for their metastatic disease.disease.
Chemotherapy Alone
Herceptin 1st line MBC Study Design
Chemotherapy (AC or Paclitaxel) Herceptin loading: 4 mg/kg weekly: 2 mg/kg
469
Patients with untreated MBCHER2 overexpression2+3+
Survival Time (months)
Pro
po
rtio
n A
live
0 5 10 15 20 25 30
0.0
0.2
0.4
0.6
0.8
1.0
Survival ALL Patients
Herceptin 79%
Control 68%
P < 0.01
Herceptin Full ApprovalHerceptin Full Approval
Survival All PatientsSurvival All Patients
Time to Progression (Months)
Pro
po
rtio
n P
rog
res
sio
n-F
ree
0 5 10 15 20 25
0.0
0.2
0.4
0.6
0.8
1.0
Time to Progression All Patients
Herceptin
Control
p < 0.001
Gemcitabine
Gemzar in combination with paclitaxel Gemzar in combination with paclitaxel is indicated for the first-line treatment is indicated for the first-line treatment of patients with metastatic breast of patients with metastatic breast cancer after failure of prior cancer after failure of prior anthracycline-containing adjuvant anthracycline-containing adjuvant chemotherapy, unless anthracyclines chemotherapy, unless anthracyclines were clinically contraindicated.were clinically contraindicated.
Paclitaxel 175 mg/m2
Days 1 and 8 q 21 days
Study Design
Gemcitabine 1250 mg/m2
Days 1 and 8 q 21 days Paclitaxel 175 mg/m2
Days 1 and 8 q 21 days
529
Unresectable,locally recurrentor metastaticbreast cancer
SurvivalSurvivalGemzar/Paclitaxel ---------- 18.6 months
Paclitaxel ---------- 15.8 months
Log rank p=0.0489
SURVIVAL
Time to Progression
ENDPOINTS
Metastatic Breast CancerMetastatic Breast Cancer
Survival: Basis of cytotoxic drug approval in 1st line MBC
Cytotoxic and biologic drugs are toxicCytotoxic and biologic drugs are toxic Survival is both a safety and an Survival is both a safety and an
efficacy parameterefficacy parameter Deaths are caused by toxicity orDeaths are caused by toxicity or
progressive disease or bothprogressive disease or both
Efficacy Reasons for using Survival as basis of approval
in 1st line MBC
Effective drugs prolong life:Effective drugs prolong life:
Doxorubicin based regimens→ 6 monthsDoxorubicin based regimens→ 6 months Herceptin → 5 monthsHerceptin → 5 months Docetaxel → 3 months Docetaxel → 3 months Capecitabine + Docetaxel → 3 months Capecitabine + Docetaxel → 3 months
Survival as a basis of approval: Examples
11stst Line MBC: Line MBC: Herceptin + PaclitaxelHerceptin + Paclitaxel Gemcitabine + PaclitaxelGemcitabine + Paclitaxel22ndnd Line MBC Line MBC Docetaxel monoterapy Docetaxel monoterapy
andand Capecitabine + Docetaxel after failure Capecitabine + Docetaxel after failure
of prior chemotherapyof prior chemotherapy
Cross-over therapy confounds survival effect:
truth or myth? According to ODAC 6/99: NoAccording to ODAC 6/99: No No literature to support this statementNo literature to support this statement A drug used after tumor progression should A drug used after tumor progression should
have the same effect in both arms, and have the same effect in both arms, and should not obscure the effect of the drug should not obscure the effect of the drug tested. Examples:tested. Examples:
Herceptin + chemo better than chemo, Herceptin + chemo better than chemo, in spite of a 65% cross-over ratein spite of a 65% cross-over rate
Camptosar + 5-FU/leucovorin better than Camptosar + 5-FU/leucovorin better than 5-FU/leucovorin, in spite of a 40% cross-5-FU/leucovorin, in spite of a 40% cross-over rateover rate
SUMMARYSUMMARY
See ODAC transcript for Monday See ODAC transcript for Monday June 7, 1999, posted on the FDA June 7, 1999, posted on the FDA
websitewebsite
TTP: Not acceptable for traditional approval in 1st line cytotoxic therapy for metastatic breast cancer
TTP as the basis of approval: Examples
22nd nd and 3and 3rdrd Line MBC Line MBC Paclitaxel Paclitaxel
LapatinibLapatinib
Progression Free Survival
Has not been used as basis for Has not been used as basis for approval in 1approval in 1stst line MBC. line MBC.
Has been used for basis of approval of Has been used for basis of approval of Ixabepilone in 2Ixabepilone in 2ndnd-3-3rdrd line therapy. line therapy.
Problems with PFS
Needs blinded RCTNeeds blinded RCT Blinded assessment by Independent Radiology Blinded assessment by Independent Radiology
ReviewReview Problems with patients without measurable Problems with patients without measurable
disease disease Problems with missed assessments or incomplete Problems with missed assessments or incomplete
assessments at baseline assessments at baseline Problems with infrequent assessmentsProblems with infrequent assessments Problems with uneven assessment in each armProblems with uneven assessment in each arm
Is the use of PFS in the 1st line treatment of MBC appropriate, especially in a situation were there is no improvement in survival?
NDA submissions based on PFS will affect survival data
Premature stopping trial before accrual is complete or stop following patients for survival
Risk for not seeing survival data in future trials